| Literature DB >> 24937266 |
Gabriele Giachin1, Joanna Narkiewicz1, Denis Scaini2, Ai Tran Ngoc1, Alja Margon3, Paolo Sequi3, Liviana Leita3, Giuseppe Legname1.
Abstract
Transmissible spongiform encephalopathies (TSE) are fatalEntities:
Mesh:
Substances:
Year: 2014 PMID: 24937266 PMCID: PMC4061048 DOI: 10.1371/journal.pone.0100016
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1MoPrP adsorption into HS affects protein solubility.
SDS-PAGE gel showing the precipitation of full-length MoPrP induced by increasing amounts of HA and FA. After adding 20 and 10 µg/mL of HS (HA and FA, respectively) the total protein is mainly present in the insoluble fractions (A). Decreased MoPrP solubility in the presence of 1 to 5 µg/mL of FA after 6 hours of incubation, and 1 to 10 µg/mL of HA after 6 and 240 hours of incubation (B). Normalized far-UV CD spectra of MoPrP after 6- and 240-hour incubation with 5 µg/mL of HS (C).
Figure 2MoPrP adsorbed into HS is protected from PK digestion.
Western-blot experiments on MoPrP (first panel), MoPrP-HA and MoPrP-FA complexes (second and third panel, respectively) incubated with different PK concentrations.
Figure 3Macroscopic characterization of humic substances.
Phase contrast optical images of HS morphology when deposited on a mica surface (20 µg/mL of FA and HA, respectively in A and D) were compared to MoPrP-HS complexes morphology deposited under the same conditions (B shows complexes between 60 µg/mL of MoPrP and FA, E depicts those with HA). Red arrows in B point at “brush-like” structures possibly ascribable to MoPrP clusters. Yellow squares highlight the FA and HA structures analyzed by AFM in panels C and D, representing three-dimensional AFM reconstructions of FA-MoPrP fractal fibers and HA-MoPrP assemblies, respectively.
Figure 4AFM characterization of HS and MoPrP-HS complexes.
Surface morphology of HS alone (HA and FA in panels A and E, respectively) and HS complexes with 25 µg/mL of MoPrP (in panels B and F corresponding to MoPrP-HA and MoPrP-FA complexes, respectively) and with 60 µg/mL of MoPrP (in panels C and G with HA and FA, respectively). Panels D and H show high magnification images of the samples presented in panels C and G.
Figure 5Effectiveness of HS in inhibiting prion replication.
ASA showing the kinetics of MoPrP fibrillization in the presence of 1 µg/mL of HS (A) and the corresponding mean value of the lag phases (in hours) for MoPrP treated with HS (**P<0.01) (B). In (C) Western-blot results showing the dose-dependent removal of PrPSc from ScGT1 cells. In the upper panel, total PrP expression detected by immunoblotting after the addition of increasing concentrations of HA and FA (here used as non-PK controls); the lower panel shows PrPSc levels after digestion with PK.